AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Not yet recruiting | Not stated | 2026-07-30 | NCT07736846 | |
| Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Recruiting | Phase 3 | 2025-05-31 | NCT06350032 | |
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2024-12-19 | NCT06514807 | |
| A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Enrolling by invitation | Not stated | 2024-08-07 | NCT06445673 | |
| Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Recruiting | Phase 4 | 2024-03-19 | NCT06317805 |